Rapamycin analogs

Rapamycin analogs has been studied in 124 papers since 2004: 22 trials and 12 observational studies in people, 25 in animals, 19 in cells, 35 reviews; 35 in the past year. The newest paper, Oct 30, 2026: “Everolimus-induced Regression of a Low-grade Oncocytic Renal Tumour in a Germline TSC1 Carrier: Expanding the Therapeutic and Phenotypic Spectrum of Tuberous Sclerosis Complex-Associated…”.

InterventionmTOR inhibitors

124 papers study it16 more mention it155 findingsUpdated

Research on it is growing 32% faster than aging research as a whole: 10 papers in the latest year counted

1 new paper in 30 daysSee all 137 papers on rapamycin analogs

At a glance

Independent labs found the same change in cells, worms or flies and people. 45 independent labs in 16 countries; 821 trials, 5 about aging, 303 with no results posted.

“The most common grade 3 or 4 adverse events were stomatitis (8% in the combination-therapy group vs. 1% in the exemestane-alone group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).”
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerThe New England journal of medicine2011doi:10.1056/nejmoa1109653

9 of its findings point the other way.

Cells, worms or flies and humans: replicated by independent labs. Mice: a single group.
  • 45 independent labs in 16 countries
  • 9 findings against
  • 821 trials, 5 about aging, 303 with no results posted
  • Funders: National Institutes of Health and others
  • 53 of 151 findings with company ties
  • 293 of 821 trials sponsored by its developers
  • Human trial22
  • Humans11
  • Animals19
  • Model organisms6
  • Cells18
  • In silico3

19 studies gave rapamycin analogs to people and measured what changed.

What changedDesignPeopleSource

up: Improves progression-free survival11.8 months vs 1.8 months

no change: Has no effect on overall survival38.3 vs 38.2 months

Randomized trial30 peopleMetastatic GEP-NEN or LCNEC after first-line chemotherapyThe oncologist, Jan 23, 2026

up: Increases seroconversion56% vs 13%

up: Increases SARS-CoV-2 IgG antibodies160 AU/mL (0–142) vs 0 AU/mL (0–0)

no change: Has no effect on cellular response44% vs 50%

Randomized trial28 d32 people12 (38%) were female72 ± 4 yElderly (≥65 y), de novo KTRsTransplantation, May 11, 2022

down: Lowers the risk of infectionP = 0.001

up: Increases antiviral gene expression

up: Improves influenza vaccination response

Randomized trial6 weeks264 peopleelderlyOlder adults; elderly subjects, low-dose combination given for 6 weeksScience translational medicine, Jul 11, 2018

no change: Has no effect on everolimus pharmacokinetic parameters across timepointsCtrough 4.7 ± 2.5 ng/mL; AUC0-12h 106 ± 51 ng/h per mL

Trialfirst 6 months after transplantation16 peopleBothmean 64 yearsOlder adults; with steady-state tacrolimusTransplantation, Sep 1, 2017

down: Decreases seizure frequencymedian reduction 39.6% high exposure and 29.3% low exposure vs 14.9% placebo

up: Increases seizure response rate40.0% vs 15.1% with placebo

up: Increases grade 3 or 4 adverse events24% high exposure, 18% low exposure, 11% placebo

Randomized trial12-week maintenance period366 people2-65 yearsAdjunctive therapy in tuberous sclerosis complex with treatment-resistant focal-onset seizuresLancet (London, England), Sep 6, 2016

What did lifespan studies of rapamycin analogs find?

DrugAge

DrugAge records 1 result from 1 paper: 1 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.

What did studies of rapamycin analogs find?

105

Studies of rapamycin analogs measured 105 outcomes; the most studied are progression-free survival (6 studies), seizure frequency (4) and cellular senescence (4).

Progression-free survival

upin humans6no changein humans1HR 0.43–0.89

6 studies
  1. Everolimus improves progression-free survival in humans (metastatic GEP-NEN or LCNEC after first-line chemotherapy) (11.8 months vs 1.8 months).

    “Median (m)PFS was 11.8 months in the everolimus arm and 1.8 months in the control arm.”

    Human trialmetastatic GEP-NEN or LCNEC after first-line chemotherapy10 mg/day

    Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial

    The oncologist

  2. Everolimus improves progression-free survival in humans (11.0 vs 3.9 months).

    “Median PFS assessed by central review was 11.0 months (95% CI, 9.2–13.3) in the everolimus arm and 3.9 months (95% CI, 3.6–7.4) in the placebo arm.”

    Human trialn = 302

    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Lancet (London, England)

  3. Everolimus increases progression-free survival in humans (hormone receptor-negative subpopulation, added to trastuzumab and paclitaxel) (median 20.27 vs 13.08 months (+7.2 months); HR 0.66).

    “hazard ratio 0·66, 95% CI 0·48-0·91; p=0·0049”

    Human trialhormone receptor-negative subpopulation, added to trastuzumab and paclitaxel10 mg once a dayn = 311

    Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

    The Lancet. Oncology

  4. Everolimus showed no clear effect on progression-free survival in humans (added to trastuzumab and paclitaxel; full study population) (HR 0.89, 95% CI 0.73-1.08; median 14.95 vs 14.49 months).

    “hazard ratio 0·89, 95% CI 0·73-1·08; p=0·1166”

    Human trialadded to trastuzumab and paclitaxel; full study population10 mg once a dayn = 719

    Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

    The Lancet. Oncology

  5. Everolimus improves progression-free survival in humans (previously treated advanced gastric cancer, compared with best supportive care) (median PFS 1.7 vs 1.4 months; HR 0.66).

    “Median PFS was 1.7 months and 1.4 months in the everolimus and placebo arms, respectively (hazard ratio, 0.66; 95% CI, 0.56 to 0.78).”

    Human trialpreviously treated advanced gastric cancer, compared with best supportive care10 mg/dn = 656

    Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

  6. Everolimus improves progression-free survival in humans (added to exemestane, compared with placebo plus exemestane) (median 6.9 vs 2.8 months (local assessment); HR 0.43 (95% CI 0.35 to 0.54)).

    “Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors.”

    Human trialadded to exemestane, compared with placebo plus exemestanen = 724

    Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

    The New England journal of medicine

  7. Everolimus improves progression-free survival in conjunction with exemestane (6.9 vs 2.8 months).

    “The trial met its primary end point, progression-free survival; the median progression-free survival, on the basis of radiographic studies assessed by the local investigators, was 6.9 months for everolimus plus exemestane versus 2.8 months for placebo plus exemestane (hazard ratio for progression or death, 0.43; 95% confidence interval [CI], 0.35 to 0.54; P<0.001”

    Human trialin conjunction with exemestanemedian duration of exposure to everolimus was 14.6 weeksfemalesn = 724

    Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

    The New England journal of medicine

  8. Everolimus improves progression-free survival in humans (median PFS 16.4 vs 11.3 months; HR 0.77 (95% CI 0.59-1.00)).

    “Everolimus plus octreotide LAR, compared with placebo plus octreotide LAR, improved progression-free survival in patients with advanced neuroendocrine tumours associated with carcinoid syndrome.”

    Human trialin combination with octreotide LAR, versus placebo plus octreotide LAR, in advanced neuroendocrine tumor with carcinoid syndrome10 mg per dayn = 429

    Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    Lancet (London, England)

Seizure frequency

downin humans4

4 studies
  1. Everolimus decreases seizure frequency in humans (median reduction 39.6% high exposure and 29.3% low exposure vs 14.9% placebo).

    “Adjunctive everolimus treatment significantly reduced seizure frequency with a tolerable safety profile compared with placebo”

    Human trialadjunctive therapy in tuberous sclerosis complex with treatment-resistant focal-onset seizures12-week maintenance periodn = 366

    Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

    Lancet (London, England)

  2. Everolimus decreases seizure frequency in humans (tuberous sclerosis complex with medically refractory epilepsy) (median reduction of 73%; 12 of 20 with at least 50% reduction).

    “Overall, seizures were reduced in 17 of the 20 by a median reduction of 73% (p<0.001).”

    Human trialtuberous sclerosis complex with medically refractory epilepsy12 weeksn = 20

    Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

    Annals of neurology

  3. Everolimus decreases seizure frequency in humans (median change -1 seizure).

    “seizure frequency for the 6-month study period (vs. the previous 6-month period) decreased in 9, did not change in 6, and increased in 1 (median change, -1 seizure; P=0.02)”

    Human trial6 monthsn = 16

    Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

    The New England journal of medicine

  4. Everolimus is linked with lower seizure frequency in humans (patient with tuberous sclerosis complex and refractory seizures).

    “A significant reduction in seizure frequency and improvement in facial angiofibromas were observed during the follow-up period.”

    Humanspatient with tuberous sclerosis complex and refractory seizures

    Late diagnosis and effective everolimus treatment in a familial case of tuberous sclerosis complex: a case report

    Frontiers in genetics

Cellular senescence

downin human cells2upin mice1downin reviews1

4 studies
  1. Everolimus induces cellular senescence in mice during treatment.

    “An induction of senescence as well as differential expression of genes responsible for metabolism was also observed”

    Animalsduring treatment

    The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor

    Frontiers in oncology

  2. Temsirolimus decreases cellular senescence in human cells (IL-1β-induced senescence) (95% CI -0.534 to -0.327).

    “senescent senescence-associated beta-galactosidase (SA-β-gal) positivity (versus rapamycin, 95% CI -0.437 to -0.230; temsirolimus, 95% CI -0.534 to -0.327”

    CellsIL-1β-induced senescencenucleus pulposus cells

    Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction

    Osteoarthritis and cartilage

  3. Everolimus decreases cellular senescence in fibroblasts from laminopathy patients with different LMNA mutations.

    “Everolimus treatment increased proliferative ability and delayed senescence in all cell lines.”

    Cellsin fibroblasts from laminopathy patients with different LMNA mutationsfibroblastn = 6

    Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts

    Proceedings of the National Academy of Sciences of the United States of America

  4. Rapamycin analogs decrease cellular senescence.

    “Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence.”

    Review

    From rapalogs to anti-aging formula

    Oncotarget

More on Cellular senescence

Stomatitis

upin humans4

4 studies
  1. Everolimus induces stomatitis in humans (grade 3 or 4 drug-related adverse events; versus placebo) (9% (18 of 202) vs 0% (0 of 98)).

    “stomatitis (in 18 [9%] of 202 patients in the everolimus group vs 0 of 98 in the placebo group)”

    Human trialgrade 3 or 4 drug-related adverse events; versus placebo10 mg per dayn = 202

    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Lancet (London, England)

  2. Everolimus increases stomatitis in humans (added to trastuzumab and paclitaxel) (67% vs 32% of patients).

    “stomatitis (314 [67%] of 472 patients in the everolimus group vs 77 [32%] of 238 patients in the placebo group)”

    Human trialadded to trastuzumab and paclitaxel10 mg once a day

    Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

    The Lancet. Oncology

  3. Everolimus increases stomatitis in humans (versus placebo) (48% (38 of 79) with everolimus vs 8% (3 of 39) with placebo).

    “The most common adverse events in the everolimus and placebo groups were stomatitis (48% [38 of 79], 8% [3 of 39], respectively)”

    Human trialversus placebo10 mg per dayn = 118

    Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

    Lancet (London, England)

  4. Everolimus increases stomatitis in combination with octreotide LAR, versus placebo plus octreotide LAR (62% vs 14% (all-grade adverse events)).

    “adverse events of all grades included stomatitis (62%vs 14%)”

    Human trialin combination with octreotide LAR, versus placebo plus octreotide LAR10 mg per dayn = 429

    Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    Lancet (London, England)

More on Stomatitis

Lifespan

upin worms2upin mice1

3 studies
  1. Temsirolimus extends lifespan in worms.

    “The rapalog temsirolimus extended lifespan similarly to rapamycin.”

    Model organisms

    Using Drugs to Slow Aging in the Nematode Caenorhabditis Elegans

    GSA 2025 abstract

  2. Temsirolimus extends lifespan in worms.

    “The rapalog temsirolimus extended lifespan similarly to rapamycin”

    Model organisms

    Characterization of Effects of mTOR Inhibitors on Aging in Caenorhabditis elegans

    The journals of gerontology. Series A, Biological sciences and medical sciences

  3. Everolimus extends lifespan in MOG35-55-immunized NOD mice.

    “mTOR inhibitors rapamycin and everolimus delayed disease progression and robustly extended survival of immunized mice”

    Animalsin MOG35-55-immunized NOD micefemales

    The mitochondriogenic but not the immunosuppressant effects of mTOR inhibitors prompt neuroprotection and delay disease evolution in a mouse model of progressive multiple sclerosis

    Neurobiology of disease

Cell proliferation

upin human cells2downin human cells1−48%

3 studies
  1. Everolimus increases cell proliferation in fibroblasts from laminopathy patients with different LMNA mutations.

    “Everolimus treatment increased proliferative ability and delayed senescence in all cell lines.”

    Cellsin fibroblasts from laminopathy patients with different LMNA mutationsfibroblastn = 6

    Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts

    Proceedings of the National Academy of Sciences of the United States of America

  2. Temsirolimus increases cell proliferation in human cells.

    “temsirolimus decreases progerin levels, increases proliferation”

    Cells

    Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype

    PloS one

  3. Everolimus inhibits cell proliferation in human cells (-48%).

    “Everolimus significantly suppressed the growth of TT cells [median inhibition concentration (IC50) 0.33 nM, maximal inhibition of proliferation: −48%] in a dose-dependent manner after 6 days of incubation.”

    Cellsmales

    Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

    Journal of cellular and molecular medicine

Overall survival

no changein humans2HR 0.9

2 studies
  1. Everolimus showed no clear effect on overall survival in humans (metastatic GEP-NEN or LCNEC after first-line chemotherapy) (38.3 vs 38.2 months).

    “MOS was similar between arms (38.3 and 38.2 months).”

    Human trialmetastatic GEP-NEN or LCNEC after first-line chemotherapy10 mg/day

    Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial

    The oncologist

  2. Everolimus showed no clear effect on overall survival in humans (previously treated advanced gastric cancer, compared with best supportive care) (median OS 5.4 vs 4.3 months; HR 0.90).

    “Median OS was 5.4 months with everolimus and 4.3 months with placebo (hazard ratio, 0.90; 95% CI, 0.75 to 1.08; P = .124)”

    Human trialpreviously treated advanced gastric cancer, compared with best supportive care10 mg/dn = 656

    Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Autophagy

upin human cells2

2 studies
  1. Temsirolimus increases autophagy in human cells.

    “Further, temsirolimus treatment enhanced autophagic activity in human chondrocytes.”

    Cells

    Temsirolimus, a water-soluble mTOR inhibitor, alleviates osteoarthritic changes in human chondrocytes and mouse osteoarthritis models

    Connective tissue research

  2. Everolimus activates autophagy in human cells.

    “Everolimus (Ever) upregulated autophagy and broadly alleviated inflammatory cytokines produced by multiple T cell subsets.”

    CellsCD4+ T cell0.01 μM

    Everolimus alleviates CD4⁺ T cell inflammation by regulating autophagy and cellular redox homeostasis

    GeroScience

More on Autophagy

Total cholesterol

upin humans2

2 studies
  1. Everolimus increases total cholesterol in humans during everolimus treatment in TSC-RAML patients.

    “Aspartate transaminase (AST), Alanine transferase (ALT), total cholesterol (TC), and triglyceride (TG) increased significantly during everolimus treatment (P < 0.05)”

    Human trialduring everolimus treatment in TSC-RAML patientsyear-long

    The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex

    Discover oncology

  2. Rapamycin analogs increase total cholesterol in individuals with ageing-related diseases.

    “there were increased numbers of infections and increases in total cholesterol, LDL cholesterol, and triglycerides in individuals with ageing-related diseases”

    Reviewin individuals with ageing-related diseases

    Targeting ageing with rapamycin and its derivatives in humans: a systematic review

    The lancet. Healthy longevity

More on Total cholesterol

Reactive oxygen species

downin cells1downin human cells1

2 studies
  1. Everolimus decreases reactive oxygen species in HGPS fibroblasts.

    “We found that both drugs effectively reduced cellular ROS levels.”

    Cellsin HGPS fibroblasts

    Peroxisomal abnormalities and catalase deficiency in Hutchinson-Gilford Progeria Syndrome

    Aging

  2. Everolimus decreases reactive oxygen species in cells (insulin-treated cultured cells).

    “They showed protective properties against genotoxic damage and significantly reduced ROS after in vitro treatment of cultured cells with insulin.”

    Cellsinsulin-treated cultured cells

    Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro

    Molecules (Basel, Switzerland)

More on Reactive oxygen species

Quality of life

upin humans2

2 studies
  1. Everolimus improves quality of life in humans (tuberous sclerosis complex with medically refractory epilepsy).

    “Significant reductions in seizure duration and improvement in parent-reported behavior and quality of life were also observed.”

    Human trialtuberous sclerosis complex with medically refractory epilepsy12 weeksn = 20

    Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

    Annals of neurology

  2. Everolimus increases quality of life in humans (mean 63.4 at 3 months and 62.1 at 6 months vs 57.8 at baseline).

    “was improved at 3 months (63.4±12.4) and 6 months (62.1±14.2) over the baseline score (57.8±14.0)”

    Human trial

    Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

    The New England journal of medicine

Estimated glomerular filtration rate

upin humans1no changein humans1

1 study
  1. Everolimus improves estimated glomerular filtration rate in humans (patients with tumor volume reduction ≥500 ml) (101 [95, 119] vs 115 [99, 122] ml/min/1.73 m2, p = 0.009).

    “Notably, patients with a tumor volume reduction (TVR) of ≥500 ml showed a significant improvement in eGFR”

    Human trialpatients with tumor volume reduction ≥500 ml1-yr

    Renal Function Outcomes in Tuberous Sclerosis Complex Patients Receiving Everolimus for Renal Angiomyolipoma

    European urology open science

  2. Everolimus showed no clear effect on estimated glomerular filtration rate in humans (overall cohort of TSC-RAML patients) (102 [81-121] vs 103 [79-122] ml/min/1.73 m2, p = 0.8).

    “After 1 yr of everolimus treatment, no significant change in eGFR was observed in the overall cohort of 54 patients”

    Human trialoverall cohort of TSC-RAML patients1-yrn = 54

    Renal Function Outcomes in Tuberous Sclerosis Complex Patients Receiving Everolimus for Renal Angiomyolipoma

    European urology open science

More on Estimated glomerular filtration rate

Calcitonin

downin humans1

1 study
  1. Everolimus decreases calcitonin in humans (combined with octreotide LAR) (86% in patient 1; 42% in patient 2).

    “Serum calcitonin decreased by 86% in patient 1 and by 42% in patient 2.”

    Human trialcombined with octreotide LAR5-10 mg/dayn = 2

    Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

    Journal of cellular and molecular medicine

  2. Everolimus decreases calcitonin.

    “This change in the dose of everolimus resulted in a marked decrease of serum calcitonin, which was substantially unchanged after the first month of treatment with 5 mg a day ( and D).”

    Human trial

    Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

    Journal of cellular and molecular medicine

More on Calcitonin

Overall response rate

upin humans1

1 study
  1. Everolimus improves overall response rate in humans (single-agent, relapsed/refractory aggressive NHL) (ORR 30% (95% CI 20-41%)).

    “The overall response rate (ORR) was 30% (95% confidence interval: 20-41%)”

    Human trialsingle-agent, relapsed/refractory aggressive NHL10 mg dailyn = 77

    A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

    Leukemia

  2. Everolimus improves overall response rate in humans (30% (23/77; 95% CI: 20 - 41%)).

    “The ORR was 30% (23/77; 95% CI: 20 - 41%) with 20 PR and 3 CRu.”

    Human trialmedian of 2.0 monthsn = 77

    A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

    Leukemia

Depressive symptoms

no changein humans1downin humans1

1 study
  1. Everolimus showed no clear effect on depressive symptoms in humans (switch from calcineurin inhibitors to everolimus, four weeks after switching) (Z = -0.595; P = .552).

    “DS (Z = -1.18; P = .236) and HAMD (Z = -0.595; P = .552) remained unchanged”

    Human trialswitch from calcineurin inhibitors to everolimus, four weeks after switching4 weeksn = 9

    Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement

    Transplantation proceedings

  2. Everolimus decreases depressive symptoms in humans (switch from calcineurin inhibitors to everolimus, four weeks after switching) (Z = -1.14; P = .048).

    “Four weeks after switching to CNI-free immunosuppression using everolimus, BDI (Z = -1.14; P = .048)”

    Human trialswitch from calcineurin inhibitors to everolimus, four weeks after switching4 weeksn = 9

    Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement

    Transplantation proceedings

All 105

What is rapamycin analogs linked with?

19

Studies link rapamycin analogs with 19 measures, among them ascites, heart failure and pleural effusion.

Ascites

upin humans1

1 study
  1. Temsirolimus is associated with ascites in humans (disproportionality signal in FAERS reports; not in drug label).

    “the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”

    Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Ascites

Heart failure

upin humans1

1 study
  1. Temsirolimus is associated with heart failure in humans (disproportionality signal in FAERS reports; not in drug label).

    “the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”

    Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Heart failure

Pleural effusion

upin humans1

1 study
  1. Temsirolimus is associated with pleural effusion in humans (disproportionality signal in FAERS reports; not in drug label).

    “the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”

    Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Pleural effusion

Dehydration

upin humans1

1 study
  1. Temsirolimus is associated with dehydration in humans (disproportionality signal in FAERS reports; not in drug label).

    “the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”

    Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Dehydration

128 adverse event preferred terms

upin humans1

1 study
  1. Temsirolimus is associated with 128 adverse event preferred terms in humans.

    “Through disproportionality analysis, we identified 128 preferred terms (PTs) associated with temsirolimus across 17 organ systems.”

    Humansdisproportionality analysis of FAERS reports; signal when ROR, PRR, BCPNN and EBGM all meet thresholdn = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

LGALS1

mixedin human cells1

1 study
  1. Everolimus is associated with LGALS1 in KMT2Ar-ALL cells.

    “inhibition of the mTOR pathway with everolimus modulated Galectin-1 expression in these cells”

    Cellsin KMT2Ar-ALL cells

    mTOR Modulation Affects Galectin-1 Expression in KMT2A-rearranged Acute Lymphoblastic Leukemia Cells

    Anticancer research

More on LGALS1

Dry age-related macular degeneration

upin humans1HR 2.14

1 study
  1. Everolimus is linked with a higher risk of dry age-related macular degeneration in humans (HR 2.14, 95% CI 1.24-3.69).

    “everolimus had an increased hazard of dry AMD (HR = 2.14, 95% CI 1.24-3.69, p < 0.01)”

    Humans

    Systemic immunosuppression and risk of age-related macular degeneration

    PloS one

More on Dry age-related macular degeneration

Infection

downin humans1

1 study
  1. Everolimus lowers the risk of infection in humans (elderly subjects, low-dose combination given for 6 weeks) (P = 0.001).

    “was associated with a significant (P = 0.001) decrease in the rate of infections reported by elderly subjects for a year after study drug initiation”

    Human trialelderly subjects, low-dose combination given for 6 weekslow-dose6 weeksn = 264

    TORC1 inhibition enhances immune function and reduces infections in the elderly

    Science translational medicine

More on Infection

Glucose intolerance

upin reviews1

1 study
  1. Rapamycin analogs are associated with glucose intolerance (chronic treatment).

    “the chronic inhibition of mTOR by macrolide rapamycin or other rapalogs has been associated with glucose intolerance and insulin resistance”

    Reviewchronic treatment

    mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?

    Oxidative medicine and cellular longevity

More on Glucose intolerance

Death

downin humans1HR 0.64

1 study
  1. Everolimus lowers the risk of death in humans (first pre-planned interim overall survival analysis; versus placebo) (HR 0.64 (95% CI 0.40-1.05), not statistically significant).

    “everolimus might be associated with a reduction in the risk of death (HR 0·64 [95% CI 0·40-1·05]”

    Human trialfirst pre-planned interim overall survival analysis; versus placebo10 mg per dayn = 302

    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Lancet (London, England)

Progression or death

downin humans1HR 0.48

1 study
  1. Everolimus lowers the risk of progression or death in humans (HR 0.48 (95% CI 0.35-0.67); median PFS 11.0 vs 3.9 months).

    “Everolimus was associated with a 52% reduction in the estimated risk of progression or death (hazard ratio [HR] 0·48 [95% CI 0·35-0·67], p<0·00001).”

    Human trialadvanced, progressive neuroendocrine tumors of lung or gastrointestinal origin; versus placebo10 mg per dayn = 302

    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Lancet (London, England)

Mortality

downin humans1HR 0.64

1 study
  1. Everolimus lowers the risk of mortality in humans (HR 0.64, 95% CI 0.40–1.05).

    “The survival results from the first interim OS analysis favoured everolimus with 36% reduction in the estimated risk relative to placebo, although statistical significance was not attained (HR, 0.64; 95% CI, 0.40–1.05; p=0.037; Lan-DeMets O’brian Fleming boundary for significance at first interim analysis, 0.0002”

    Human trialn = 302

    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Lancet (London, England)

Disease progression or death

downin humans1HR 0.48

1 study
  1. Everolimus lowers the risk of disease progression or death in humans (HR 0.48, 95% CI 0.35–0.67).

    “Everolimus was associated with a 52% reduction in the estimated risk of disease progression or death (HR, 0.48; 95% CI, 0.35–0.67; p<0.00001).”

    Human trialn = 302

    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Lancet (London, England)

Stomatitis

upin humans1

1 study
  1. Everolimus raises the risk of stomatitis in conjunction with exemestane (8% vs. 1%).

    “The most common grade 3 or 4 adverse events were stomatitis (8% in the combination-therapy group vs. 1% in the exemestane-alone group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).”

    Human trialin conjunction with exemestanemedian duration of exposure to everolimus was 14.6 weeksfemalesn = 724

    Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

    The New England journal of medicine

More on Stomatitis

Thrombocytopenia

upin humans1

1 study
  1. Everolimus raises the risk of thrombocytopenia in humans (versus ciclosporin-based regimen).

    “thrombocytopenia, aphthous stomatitis, and diarrhoea also occurred more often in the everolimus group”

    Human trialversus ciclosporin-based regimen

    Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

    Lancet (London, England)

More on Thrombocytopenia

All 19

Trials

5 of 821 about aging

Who is developing rapamycin analogs?

3 companies: Novartis Pharmaceuticals, Chong Kun Dang Pharmaceutical and Eisai.

Companies
  • Novartis PharmaceuticalseverolimusPhase 4renal angiomyolipoma, pancreatic neuroendocrine tumor
  • Chong Kun Dang PharmaceuticaleverolimusPhase 4heart transplant
  • EisaieverolimusPhase 3renal cell carcinoma

Trial sponsors

Funding

1 grant since 2018

National Eye Institute$1.3M

Latest

Dec 2025: 9Jan 2026: 9Feb 2026: 4Mar 2026: 5Apr 2026: 0May 2026: 2Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 2Oct 2026: 1Nov 2026: 033 papers in 12 months

See all 137 papers on rapamycin analogs